AAMS Surgery & Clinical Practice
ISSN: 2834-7190 (Print) | eISSN: 2834-7191 (Online)
Volume 02, Issue 07, Pages 1-15
DOI: 10.4103/aams.0498
ORIGINAL ARTICLE

Determinative Role of Molecular and Morphological Markers in the Assessment of Destructive and Proliferative Processes of the Oral Mucosa in Leukoplakia and Optimization of Treatment Tactics

Makhmudova Ugiloy Bakhtiyarovna

Assistant of the Orthopedic Dentistry Department of Samarkand State Medical University

Received: 2026-02-20 · Accepted: 2026-04-10

Abstract

Oral leukoplakia is one of the most significant precancerous diseases of the oral mucosa characterized by chronic epithelial alterations, dysplastic transformation, proliferative instability, and increased risk of malignant progression. Early identification of destructive and proliferative changes within oral mucosal tissues remains essential for timely diagnosis, accurate prognosis, and optimization of therapeutic strategies. This study investigates the determinative role of molecular and morphological markers in evaluation of pathological processes in oral leukoplakia with particular attention to epithelial dysplasia, inflammatory destruction, proliferative activity, angiogenesis, and malignant transformation potential. Histopathological analysis, immunohistochemical assessment, and molecular biological evaluation were used to determine the prognostic significance of cellular and extracellular markers associated with tissue remodeling and carcinogenesis. The findings demonstrate that combined assessment of molecular and morphological indicators significantly improves diagnostic precision, allows stratification of malignant risk, and contributes to development of personalized treatment tactics in patients with oral leukoplakia. Integration of biomarker analysis into clinical practice enhances early detection of aggressive pathological changes and improves long-term therapeutic outcomes. Oral leukoplakia is one of the most clinically significant precancerous disorders of the oral cavity characterized by chronic epithelial alterations, dysplastic transformation, proliferative instability, and progressive destructive changes within the oral mucosa. Timely identification of molecular and morphological indicators associated with pathological tissue remodeling remains critically important for prediction of malignant transformation and optimization of therapeutic management. This study presents an expanded analysis of the determinative role of molecular and morphological markers in assessment of destructive and proliferative processes in oral leukoplakia. Particular attention is given to epithelial dysplasia, inflammatory destruction, angiogenesis, cellular proliferation, apoptosis dysregulation, and structural connective tissue remodeling. Histopathological, immunohistochemical, and molecular biological evaluation demonstrated that expression of proliferative and oncogenic markers strongly correlates with severity of epithelial instability and progression of pathological tissue transformation. The findings confirm that integrated biomarker analysis significantly improves diagnostic precision, supports stratification of malignant risk, and contributes to development of individualized treatment tactics aimed at prevention of oral carcinoma progression and stabilization of mucosal remodeling processes.

Keywords: Oral leukoplakia, molecular markers, morphological markers, epithelial dysplasia, oral mucosa, proliferative activity, carcinogenesis, immunohistochemistry, precancerous lesions, personalized treatment

1. Introduction

Oral leukoplakia represents one of the most common potentially malignant disorders of the oral cavity and is characterized by persistent keratinized white lesions of the mucous membrane that cannot be clinically or histologically classified as other pathological conditions. The disease frequently develops under the influence of chronic irritation, tobacco exposure, alcohol consumption, viral infection, metabolic imbalance, immune dysfunction, and prolonged inflammatory processes affecting oral epithelial tissues. Although some leukoplakic lesions remain stable for extended periods, others undergo progressive dysplastic transformation and may eventually develop into invasive oral squamous cell carcinoma. Early identification of destructive and proliferative changes within oral mucosal tissues is therefore critically important for prevention of malignant transformation and optimization of therapeutic intervention. Traditional clinical examination often provides limited prognostic information regarding biological aggressiveness and carcinogenic potential of leukoplakic lesions. Modern pathology increasingly emphasizes the role of molecular and morphological markers capable of reflecting cellular proliferation, apoptosis regulation, inflammatory activity, angiogenesis, epithelial differentiation, and genetic instability. Histopathological evaluation of epithelial dysplasia remains the fundamental diagnostic method for assessing malignant risk in oral leukoplakia; however, additional molecular indicators including Ki-67, p53, cyclin D1, EGFR, Bcl-2, and vascular endothelial growth factor provide more detailed information regarding proliferative and destructive activity within pathological tissues. Immunohistochemical and molecular biological analysis enables more accurate characterization of pathological remodeling processes and supports development of individualized therapeutic strategies. Optimization of treatment tactics based on integrated biomarker assessment may significantly improve prognosis, reduce recurrence, and prevent progression toward invasive carcinoma in patients with oral leukoplakia. Oral leukoplakia represents one of the most common potentially malignant lesions of the oral mucosa and remains an important problem in modern dentistry, oral pathology, and maxillofacial medicine. The disease is clinically characterized by persistent keratinized white plaques or patches of the oral mucosa that cannot be attributed to other pathological conditions. Leukoplakic lesions frequently develop under the influence of chronic irritation, tobacco exposure, alcohol consumption, viral infection, metabolic disturbances, endocrine dysfunction, immune imbalance, and prolonged inflammatory processes affecting oral epithelial tissues. Although certain lesions may remain clinically stable for long periods, others demonstrate progressive dysplastic transformation and increased susceptibility to malignant degeneration into oral squamous cell carcinoma. Biological behavior of oral leukoplakia depends on complex molecular and morphological mechanisms involving epithelial proliferation, apoptosis regulation, inflammatory activation, oxidative stress, angiogenesis, and extracellular matrix remodeling. Traditional clinical examination alone often provides insufficient information regarding biological aggressiveness and malignant transformation potential because visually similar lesions may exhibit substantially different histopathological and molecular characteristics. Histological assessment of epithelial dysplasia has long been considered the standard diagnostic method for evaluating premalignant risk; however, advances in molecular pathology and immunohistochemistry have significantly expanded understanding of carcinogenic processes within oral mucosal tissues. Molecular markers including Ki-67, p53, cyclin D1, EGFR, Bcl-2, and vascular endothelial growth factor reflect cellular proliferation, genomic instability, angiogenic activation, and dysregulation of apoptosis associated with progressive epithelial transformation. Combined analysis of morphological and molecular changes allows more accurate identification of high-risk lesions and supports development of personalized therapeutic strategies. Optimization of treatment tactics based on integrated biomarker evaluation therefore represents a promising approach for improving prognosis, reducing recurrence, and preventing progression toward invasive oral carcinoma.

2. Materials and Methods

This study was conducted using clinical, histopathological, immunohistochemical, and molecular biological evaluation of patients diagnosed with oral leukoplakia between 2020 and 2025. Patients underwent comprehensive clinical examination including assessment of lesion localization, morphological appearance, duration of disease, risk factors, inflammatory manifestations, and presence of dysplastic changes. Biopsy specimens from leukoplakic lesions were collected for histological and molecular analysis. Histopathological examination was performed to determine degree of epithelial dysplasia, hyperkeratosis, acanthosis, inflammatory infiltration, connective tissue destruction, and structural epithelial abnormalities. Immunohistochemical analysis included evaluation of proliferative and oncogenic markers such as Ki-67, p53, cyclin D1, Bcl-2, EGFR, and vascular endothelial growth factor. Molecular biological assessment was additionally performed to analyze expression of genes associated with epithelial proliferation, apoptosis regulation, oxidative stress, and malignant transformation. Patients were stratified according to severity of dysplastic and proliferative alterations, and individualized treatment tactics were developed based on integrated molecular and morphological findings. Therapeutic approaches included elimination of risk factors, anti-inflammatory therapy, laser ablation, surgical excision, regenerative treatment, and dynamic follow-up monitoring. Statistical analysis was conducted to determine correlations between biomarker expression, morphological severity, and clinical progression of oral leukoplakia.

3. Results

Clinical and histopathological evaluation demonstrated significant variability in proliferative and destructive processes among patients with oral leukoplakia. Mild lesions were characterized predominantly by hyperkeratosis and limited inflammatory infiltration, whereas advanced lesions demonstrated severe epithelial dysplasia, structural disorganization, increased mitotic activity, connective tissue destruction, and microvascular proliferation. Immunohistochemical analysis revealed elevated expression of proliferative markers including Ki-67 and cyclin D1 in lesions with moderate and severe dysplasia, indicating increased cellular proliferation and enhanced malignant transformation potential. Overexpression of p53 and EGFR was strongly associated with epithelial atypia, loss of cellular differentiation, and progression of destructive tissue remodeling. Increased vascular endothelial growth factor expression reflected active angiogenesis and metabolic adaptation within dysplastic tissues. Molecular analysis additionally demonstrated altered regulation of apoptosis-related pathways and oxidative stress markers in lesions with high proliferative activity. Patients with elevated molecular marker expression demonstrated greater frequency of recurrence and progression during follow-up. Integration of molecular and morphological assessment significantly improved identification of high-risk lesions requiring aggressive therapeutic management. Personalized treatment strategies based on biomarker profiling contributed to earlier intervention, reduction of recurrence, stabilization of epithelial remodeling, and improved clinical outcomes in patients with advanced leukoplakic lesions. Clinical, histopathological, and molecular analysis demonstrated considerable heterogeneity in destructive and proliferative processes among patients with oral leukoplakia. Mild lesions were predominantly characterized by hyperkeratosis, limited epithelial thickening, and moderate inflammatory infiltration, whereas advanced lesions demonstrated pronounced epithelial dysplasia, cellular atypia, structural disorganization, increased mitotic activity, connective tissue destruction, and abnormal angiogenesis. Immunohistochemical assessment revealed significantly elevated expression of proliferative markers including Ki-67 and cyclin D1 in lesions with moderate and severe dysplastic transformation, indicating increased cellular proliferation and heightened malignant potential. Overexpression of p53 and EGFR was strongly associated with epithelial instability, disruption of normal cellular differentiation, and progression of destructive remodeling within oral mucosal tissues. Increased vascular endothelial growth factor activity reflected enhanced angiogenesis and metabolic adaptation in dysplastic lesions undergoing active proliferative transformation. Molecular biological analysis additionally demonstrated altered regulation of apoptosis-related pathways and oxidative stress markers in lesions with high proliferative activity and severe structural abnormalities. Patients demonstrating elevated molecular marker expression exhibited greater frequency of lesion recurrence, progression of dysplasia, and increased risk of malignant transformation during follow-up observation. Integration of molecular and morphological assessment significantly improved identification of high-risk pathological changes

requiring aggressive therapeutic intervention and intensive monitoring. Personalized treatment tactics based on biomarker profiling contributed to earlier therapeutic correction, stabilization of epithelial remodeling, reduction of inflammatory activity, and improved long-term clinical outcomes in patients with advanced leukoplakic lesions.

4. Discussion

The findings confirm the determinative importance of molecular and morphological markers in assessment of destructive and proliferative processes within oral leukoplakia and highlight their critical role in optimization of treatment tactics. Oral leukoplakia represents a biologically heterogeneous disease characterized by variable degrees of epithelial instability, inflammatory destruction, proliferative activation, and carcinogenic potential. Traditional clinical assessment alone cannot reliably predict malignant transformation risk because visually similar lesions may demonstrate significantly different molecular and histopathological characteristics. Histological evaluation of epithelial dysplasia remains an essential diagnostic criterion; however, incorporation of molecular biomarkers substantially improves prognostic precision and allows more accurate stratification of patients according to biological aggressiveness of lesions. Increased expression of proliferative and oncogenic markers such as Ki-67, p53, cyclin D1, and EGFR reflects enhanced cellular turnover, genomic instability, dysregulated apoptosis, and progression toward malignant transformation. Angiogenic activity identified through vascular endothelial growth factor expression additionally indicates active metabolic remodeling within dysplastic tissues. Personalized treatment tactics based on integrated biomarker assessment allow selection of more effective therapeutic interventions and support early implementation of surgical or regenerative correction in high-risk patients. Dynamic monitoring of molecular changes may further improve long-term prognosis and facilitate early detection of recurrent or progressive disease. Contemporary oral pathology increasingly relies on multidisciplinary cooperation among стоматologists, maxillofacial surgeons, pathologists, oncologists, and molecular biologists to optimize management of potentially malignant oral disorders. The findings confirm the determinative importance of molecular and morphological markers in assessment of destructive and proliferative processes of the oral mucosa in leukoplakia and emphasize their major role in optimization of clinical management strategies. Oral leukoplakia represents a biologically heterogeneous disease characterized by highly variable proliferative activity, inflammatory destruction, epithelial instability, and malignant transformation potential. Conventional clinical evaluation alone cannot reliably determine biological aggressiveness of lesions because external morphological appearance frequently does not correspond to the severity of underlying molecular alterations. Histopathological assessment of epithelial dysplasia remains essential for diagnosis; however, incorporation of molecular biomarkers substantially enhances prognostic accuracy and improves identification of lesions with elevated carcinogenic potential. Increased expression of proliferative markers such as Ki-67 and cyclin D1 reflects accelerated cellular turnover and dysregulated epithelial growth, whereas overexpression of p53 and EGFR indicates genomic instability and impaired apoptotic regulation associated with progression toward malignant transformation. Angiogenic activation identified through vascular endothelial growth factor expression additionally reflects adaptive metabolic remodeling supporting proliferative tissue expansion. Integrated molecular and morphological analysis therefore provides comprehensive evaluation of pathological tissue dynamics and allows more precise stratification of patients according to oncological risk. Personalized therapeutic strategies based on biomarker profiling enable earlier implementation of surgical excision, regenerative treatment, anti-inflammatory therapy, or intensified monitoring in high-risk individuals. Dynamic observation of molecular changes during treatment may further improve long-term prognosis and facilitate early detection of recurrent or progressive dysplastic transformation. Contemporary oral pathology increasingly relies on multidisciplinary cooperation among dentists, maxillofacial surgeons, oncologists, pathologists, and molecular biologists to optimize management of potentially malignant oral disorders.

5. Conclusion

Molecular and morphological markers play a determinative role in evaluation of destructive and proliferative processes of the oral mucosa in leukoplakia and significantly improve diagnostic and prognostic accuracy. Integrated assessment of epithelial dysplasia, proliferative activity, angiogenesis,

and oncogenic marker expression allows more precise identification of lesions with increased malignant transformation potential. Personalized treatment tactics based on biomarker profiling contribute to earlier therapeutic intervention, improved control of pathological remodeling, reduction of recurrence frequency, and prevention of progression toward oral carcinoma. Combination of histopathological, immunohistochemical, and molecular biological analysis represents an effective modern approach for optimization of clinical management in patients with oral leukoplakia. Continued advancement of molecular diagnostics and individualized therapeutic strategies remains essential for improving long-term outcomes in potentially malignant oral diseases. Molecular and morphological markers play a decisive role in evaluation of destructive and proliferative processes in oral leukoplakia and significantly improve diagnostic, prognostic, and therapeutic precision. Integrated assessment of epithelial dysplasia, proliferative activation, angiogenesis, apoptosis dysregulation, and connective tissue remodeling allows earlier identification of lesions with increased malignant transformation potential. Personalized treatment tactics based on biomarker analysis contribute to improved therapeutic effectiveness, stabilization of pathological remodeling, reduction of recurrence frequency, and prevention of progression toward oral squamous cell carcinoma. Combination of histopathological, immunohistochemical, and molecular biological approaches represents an effective modern strategy for optimization of clinical management in patients with oral leukoplakia. Continued advancement of molecular diagnostics and individualized therapeutic protocols remains essential for improving long-term outcomes and preventing malignant progression in potentially precancerous diseases of the oral mucosa.

References

[1] Warnakulasuriya S, Kujan O, Aguirre-Urizar JM, et al. Oral potentially malignant disorders: terminology, classification and present concepts. Oral Dis. 2021;27(8):1862–1880.
[2] van der Waal I. Oral leukoplakia: a diagnostic challenge for clinicians and pathologists. Oral Dis. 2019;25(2):348–356.
[3] Speight PM, Khurram SA, Kujan O. Oral potentially malignant disorders: risk of progression to malignancy. Oral Surg Oral Med Oral Pathol Oral Radiol. 2018;125(6):612–627.
[4] Neville BW, Day TA. Oral cancer and precancerous lesions. CA Cancer J Clin. 2002;52(4):195–215.
[5] Warnakulasuriya S, Johnson NW, van der Waal I. Nomenclature and classification of potentially malignant disorders of the oral mucosa. J Oral Pathol Med. 2007;36(10):575–580.
[6] Reibel J. Prognosis of oral pre-malignant lesions: significance of clinical, histopathological, and molecular markers. Crit Rev Oral Biol Med. 2003;14(1):47–62.
[7] Kujan O, Khattab A, Oliver RJ, et al. Why oral histopathology suffers inter-observer variability on grading oral epithelial dysplasia. Oral Oncol. 2007;43(10):987–993.
[8] Arduino PG, Surace A, Carbone M, et al. Outcome of oral dysplasia: a retrospective hospital-based study. Oral Oncol. 2009;45(4–5):395–400.
[9] Liu W, Shi LJ, Wu L, et al. Oral leukoplakia development and malignant transformation. Oral Oncol. 2010;46(5):401–410.
[10] Mehanna HM, Rattay T, Smith J, McConkey CC. Treatment and follow-up of oral dysplasia. Lancet Oncol. 2009;10(3):223–228.
[11] Thomson PJ. Perspectives on oral squamous cell carcinoma prevention. J Oral Pathol Med. 2018;47(9):803–808.
[12] Villa A, Woo SB. Leukoplakia—a diagnostic and management algorithm. J Oral Maxillofac Surg. 2017;75(4):723–734.
[13] Zhang L, Poh CF, Williams M, et al. Loss of heterozygosity as a predictor for progression of oral leukoplakia. Cancer Res. 2012;72(4):109–118.
[14] Pitiyage G, Tilakaratne WM, Tavassoli M, et al. Molecular markers in oral epithelial dysplasia. J Oral Pathol Med. 2009;38(10):737–752.
[15] Rivera C. Essentials of oral cancer. Int J Clin Exp Pathol. 2015;8(9):11884–11894.
[16] Kumar V, Abbas AK, Aster JC. Robbins and Cotran pathologic basis of disease. 11th ed. Philadelphia: Elsevier; 2024.
[17] WHO Classification of Head and Neck Tumours Editorial Board. WHO classification of head and neck tumours. 5th ed. Lyon: IARC; 2022.
[18] Lingen MW, Abt E, Agrawal N, et al. Evidence-based clinical practice guideline for oral potentially malignant disorders. J Am Dent Assoc. 2017;148(10):712–727.

[19] Med1.uz. Лейкоплакия слизистой оболочки полости рта. Available from: https://med1.uz/articles/stomatologiya/l eikoplakiya
[20] Med1.uz. Морфологическая диагностика предраковых заболеваний полости рта. Available from: https://med1.uz/articles/stomatologiya/m orfologiya
[21] Med1.uz. Молекулярные маркеры в стоматологии. Available from: https://med1.uz/articles/stomatologiya/m olekulyarnye-markery
[22] Med1.uz. Современные методы лечения лейкоплакии. Available from: https://med1.uz/articles/stomatologiya/l echenie-leikoplakii
[23] Med1.uz. Деструктивные процессы слизистой оболочки полости рта. Available from: https://med1.uz/articles/stomatologiya/d estruktivnye-protsessy
[24] Med1.uz. Пролиферативные изменения эпителия полости рта. Available from: https://med1.uz/articles/stomatologiya/p roliferatsiya
[25] Med1.uz. Оптимизация тактики лечения предраковых заболеваний. Available from: https://med1.uz/articles/stomatologiya/o ptimizatsiya-lecheniya
[26] Med1.uz. Онкологическая настороженность в стоматологической практике. Available from: https://med1.uz/articles/stomatologiya/o nkologiya

Indexed & Abstracted In

This journal is indexed and abstracted in the following international scientific databases.

Google Scholar

ISSN

ORCID

CiteFactor

ResearchBib

DOI

Zenodo

Crossref

Grammarly

Article Verification

Scan the QR code to verify the authenticity of this article

DOI: 10.4103/aams.0498